Gemfibstad 300

Gemfibrozil is used in the treatment of hyperlipidaemias. Gemfibrozil decreases triglyceride rich lipoproteins concentrations, such as VLDL (very-low-density lipoprotein), slightly increases HDL (high-density lipoprotein) and variable effects on LDL-cholesterol. Gemfibrozil is also used to reduce plateletaggregation that reduce the risk of macrovascular disease.

Pack size Box of 60 capsules, 100 capsules
Shelf-life 24 months
Composition Gemfibrozil
Dosage forms and strengths Hard-gelatin capsule: 300 mg.
Product code :



  • Treatment of homozygous hyperlipidaemias (type III). Moderate and severe hypertriglyceridemias develop the risk of pancreatitis. Familial combined hyperlipidaemias, have elevated concentrations of VLDL; if elevated concentrations of LDL, patients can be indicated to add HMG CoA reductase inhibitors at low dose.
  • Treatment of hyperlipidaemias and reduction of the risk of developing coronary heart disease (CHD) in patients with type IIb hyperlipoproteinemia without clinical evidence of CHD (primary prevention) who have an inadequate response to dietary management, weight loss, exercise, or drug with single therapy and who have the following triad of lipid abnormalities: Low HDLcholesterol concentrations in addition to elevated LDL-cholesterol and triglycerides.
  • Primary severe hypertriglyceridaemia (type IV hyperlipoproteinemia and type V hyperlipoproteinemia) who have a risk of coronary artery disease or recurrent abdominal pain typical of pancreatitis not responsive to dietary management and other single measures.


The usual adult dosage of gemfibrozil is 600 mg twice daily. The drug should be discontinued after 3 months if serum lipoprotein concentrations do not improve substantially.


Gemfibstad 300 is administered orally, 30 minutes before the morning and evening meals.

Known hypersensitivity to any of the active substance or excipients.

Pregnancy and children.

Renal or hepatic dysfunction, gallbladder disease, primary biliary cirrhosis.

Dyspepsia, abdominal pain, diarrhea, nausea, vomiting, constipation, acute appendicitis. Cholelithiasis. Fatigue, vertigo, headache. Eczema, rash.

If myositis is suspected or diagnosed (patients who complain of muscle pain, tenderness, or weakness), or gallstones are found, gemfibrozil should be discontinued.

Gemfibrozil should not be used when breast-feeding.

Gemfibrozil is not indicated for treatment in patients with type I hyperlipoproteinemia.

Patients should be aware of how they react to drug before driving or operating machinery.